Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets ...
Hosted on MSN
Evercore ISI Group downgrades Bio-Techne (TECH)
Fintel reports that on January 5, 2026, Evercore ISI Group downgraded their outlook for Bio-Techne (NasdaqGS:TECH) from Outperform to In-Line. Analyst Price Forecast Suggests 13.02% Upside As of ...
Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.64% to 6,902.05 and the ...
Learn the benefits and risks of options and how to start trading options Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Samantha (Sam) Silberstein, CFP®, CSLP®, ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback